Breast cancer is the second most common cause of death after lung cancer in developing countries. There is a great need to expand the range of biomarkers to identify patients that can be treated using new therapies. Epigenetic silencing of amino acid regulatory genes have been postulated as a predictive biomarker in breast cancer and treatment based on modulating amino acid levels have been shown to be effective in other cancers. In this study, I have examined how the amino acid regulatory genes for glutamine (Glutamine synthetase, GLUL) and arginine (Arginino-succinate synthetase, ASS1) synthesis are silenced via methylation in a panel of breast cancer cell lines.
|Date of Award||Jun 2014|